聚乙二醇化重组人粒细胞刺激因子预防卵巢癌化疗粒细胞减少症的临床治疗

[1]	石远凯, 徐建萍, 吴昌平,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对期临床研究[J]. 中国肿瘤临床,2017,44(14):679-684.
[2]	Pfeil A M, Allcott K, Pettengell R,et al. Efficacy,effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review[J]. Support Care Cancer,2015,23(2):525-545.
[3]	Pawloski P A, Larsen M, Thoresen A,et al. Pegfilgrastim use and bone pain:a cohort study of community-based cancer patients[J]. J Oncol Pharmy Pract,2016,22(3):423-429.
[4]	徐兵河, 田富国, 喻璟瑞,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对期临床研究[J]. 中华肿瘤杂志,2016,38(1):23-27.
[5]	Usami E,Kimura M,Iwai M,et al. The incidence and timing of leukocyte overshoot after pegfilgrastim administration[J]. J Oncol Pharm Pract,2019,25(4):869-874.